Key opportunities in the Global Small Cell Lung Cancer Therapeutics Market include the growing demand for advanced ...

The study, published in British scientific journal Nature, suggests that the disease may begin in basal stem cells — long-lived cells that help repair and replace damaged tissue in the lungs — ...

Durvalumab cost-effectiveness in limited-stage small cell lung cancer failed to meet US value thresholds despite longer ...

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common complication of small cell lung cancer (SCLC). It can cause many symptoms related to low sodium or other electrolyte ...

Is Zepzelca Right for Me? To help choose the right treatment for you, your health care provider will consider what type of lung cancer you have, the treatments you have received, and whether the ...

Despite a significant 48.8% objective response rate and breakthrough therapy status, this regulatory shift reverses years of ...

The phase 3 IMforte trial(NCT05091567) demonstrated benefit for expanding on maintenance immunotherapy in extensive-stage ...

A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...

Study Results Support the use of TellDx to Personalize Cancer Care Management –-- Clinical study published in Cancer Discovery --ANDOVER, ...